These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37558354)
1. Can Deep Learning Detect Incidental Abnormal Cardiac Uptake Related to Amyloidosis on Routine Bone Scintigraphy? Slomka PJ; Miller RJH JACC Cardiovasc Imaging; 2023 Aug; 16(8):1096-1098. PubMed ID: 37558354 [No Abstract] [Full Text] [Related]
2. Deep Learning on Bone Scintigraphy to Detect Abnormal Cardiac Uptake at Risk of Cardiac Amyloidosis. Delbarre MA; Girardon F; Roquette L; Blanc-Durand P; Hubaut MA; Hachulla É; Semah F; Huglo D; Garcelon N; Marchal E; El Esper I; Tribouilloy C; Lamblin N; Duhaut P; Schmidt J; Itti E; Damy T JACC Cardiovasc Imaging; 2023 Aug; 16(8):1085-1095. PubMed ID: 37227330 [TBL] [Abstract][Full Text] [Related]
3. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. Treibel TA; Bandula S; Fontana M; White SK; Gilbertson JA; Herrey AS; Gillmore JD; Punwani S; Hawkins PN; Taylor SA; Moon JC J Cardiovasc Comput Tomogr; 2015; 9(6):585-92. PubMed ID: 26209459 [TBL] [Abstract][Full Text] [Related]
4. Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy. Layoun ME; Desmarais J; Heitner SB; Masri A Eur Heart J; 2020 Jul; 41(25):2414. PubMed ID: 32077932 [No Abstract] [Full Text] [Related]
5. [Bone seeking tracers' scintigraphy for the diagnosis of transthyretin cardiac amyloidosis]. Daquarti GJ; Meretta A; Corneli M; Costabel JP; Diez M; Masoli OH Medicina (B Aires); 2018; 78(6):395-398. PubMed ID: 30504105 [TBL] [Abstract][Full Text] [Related]
6. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Gertz MA; Brown ML; Hauser MF; Kyle RA Arch Intern Med; 1987 Jun; 147(6):1039-44. PubMed ID: 3036031 [TBL] [Abstract][Full Text] [Related]
7. Antimyosin scintigraphy for detection of cardiac amyloidosis. Lekakis J; Dimopoulos M; Nanas J; Prassopoulos V; Agapitos N; Alexopoulos G; Palazis L; Kostamis P; Stamatelopoulos S; Moulopoulos S Am J Cardiol; 1997 Oct; 80(7):963-5. PubMed ID: 9382020 [TBL] [Abstract][Full Text] [Related]
9. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Glaudemans AW; van Rheenen RW; van den Berg MP; Noordzij W; Koole M; Blokzijl H; Dierckx RA; Slart RH; Hazenberg BP Amyloid; 2014 Mar; 21(1):35-44. PubMed ID: 24455993 [TBL] [Abstract][Full Text] [Related]
10. Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis. Simons M; Isner JM Am J Cardiol; 1992 Feb; 69(4):425-7. PubMed ID: 1734663 [No Abstract] [Full Text] [Related]
11. Bone scintigraphy for cardiac amyloidosis: A Canadian perspective. Miller RJ; Akincioglu C J Med Imaging Radiat Sci; 2024 Jun; 55(2S):S39-S43. PubMed ID: 38461059 [No Abstract] [Full Text] [Related]
12. Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. Musumeci MB; Cappelli F; Russo D; Tini G; Canepa M; Milandri A; Bonfiglioli R; Di Bella G; My F; Luigetti M; Grandis M; Autore C; Perlini S; Perfetto F; Rapezzi C JACC Cardiovasc Imaging; 2020 Jun; 13(6):1314-1321. PubMed ID: 31864976 [TBL] [Abstract][Full Text] [Related]
13. Validation of the Kumamoto criteria for prediction of Ochi Y; Kubo T; Baba Y; Ueda M; Miyagawa K; Noguchi T; Hirota T; Yamasaki N; Kitaoka H J Cardiol; 2021 Feb; 77(2):124-130. PubMed ID: 33132078 [TBL] [Abstract][Full Text] [Related]
14. Recommendations for good clinical practice for DPD bone scintigraphy for cardiac amyloidosis. Wechalekar K; Hutt D; Quigley AM; Whelan C; Chan PS; Hossen L; Armstrong I; Arumugam P; Moody W; Wechalekar AD Nucl Med Commun; 2024 Apr; 45(4):253-262. PubMed ID: 38275011 [No Abstract] [Full Text] [Related]